CN101091713A - Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage - Google Patents
Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage Download PDFInfo
- Publication number
- CN101091713A CN101091713A CN 200610200582 CN200610200582A CN101091713A CN 101091713 A CN101091713 A CN 101091713A CN 200610200582 CN200610200582 CN 200610200582 CN 200610200582 A CN200610200582 A CN 200610200582A CN 101091713 A CN101091713 A CN 101091713A
- Authority
- CN
- China
- Prior art keywords
- tripterine
- disease
- trehalose
- capsule
- usage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a tripterine capsule for preventing and curing the diseases due to nerve injury and its preparation method. Said capsule is made up by using natural tripterine whose purity is 98% as main raw material and adding natural mycose whose purity is 98% as auxiliary material through a certain preparation process. Said tripterine capsule can be mainly used for curing the diseases of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and other diseases due to nerve injury.
Description
Technical field
Patent of the present invention " prevention and treatment disease of nerve damage tripterine capsule and preparation method thereof and usage " relates to and uses purity is primary raw material greater than the tripterine of 98% natural origin, composite purity is greater than the trehalose of 98% natural origin, make capsule, be used for treatment of diseases such as disease of nerve damage such as Alzheimer (AD), parkinson (PD), Heng Tingdunshi disease (HD), oblongata Duchenne-Arandisease (KD), lateral spinal sclerosis disease (ALS) and spinal cord injury.These diseases come from the functional protein structure alienation in the cranial nerve cell and curl, and can't exercise normal function and cause disease, at present, do not have the good curing method.Trehalose has the effect of the functional protein structure alienation formation that hinders in the cranial nerve cell, tripterine can not only hinder the effect that the functional protein structure alienation in the cranial nerve cell forms in addition, and has the functional protein that can make in the cranial nerve of having curled to be returned to the effect of proteic structure of normal function and function.Thereby a kind of tripterine capsule for preparing pure natural components of patent of the present invention can be treated the nerve injury disease.
Background technology
List of references [1] " purposes of tripterygium plant extract in prevention and treatment nervous system disease " number of patent application CN00107779.1 has described the present invention and has prevented and the treatment nervous system disease for a kind of tripterygium plant extract.Described nervous system disease comprises Alzheimer, parkinson disease, Heng Tingdunshi neurodegenerative diseases and spinal cord injury, lateral spinal sclerosis disease.Monomer component in the Thunder God Calamus extract not only has significant immunosuppressive activity under the experiment condition in stripped and body; also the DA serotonergic neuron of cultivating had tangible Nutrition; the growth of cranial nerve cell in can promoting; promote the projection of the former foster cortical neurogenic cell of being commissioned to train to prolong; can the antagonism environmental toxin; endogenous toxin and excitatory neuron toxin are to the nerve cell damage effect; the survival of pair cell has significant protective effect; this patent fails to illustrate that any Radix Tripterygii Wilfordii monomer component is quantitative criterion extract and preparation method, has only proposed the function and protecting of tripterygium plant extract.This invention fails to illustrate that tripterine is an effective ingredient, does not also show the content of tripterine, does not more have tripterine and trehalose composite and make capsule and using method thereof.List of references [2] USA patent 5,880116 (1999) " tripterine is used for the treatment of Alzheimer ", this patent relates to Radix Tripterygii Wilfordii extract to taking medicine, relevant dose and take method, rather than tripterine single component or tripterine and the composite using method of trehalose.List of references [3] USA number of patent application 20040220267 " derivant of five rings demethyl triterpene quinone is used for inflammation, nerve damage and tumor disease "; this patent application claims: use the tripterine and the derivant of pristimerin such as the acetylate of their dihydro thing and dihydro thing to treat inflammation, nerve damage and tumor disease, and the preparation method of derivant.Tested the reactive compound that 1040 NINDS (the state-run sacred disease institute of the U.S.) collect in the list of references [4] " reverse of total length variation Huntingdon neuronal cell phenotype is regulated cumulative chemical inhibitor by polymerization glutamic acid ", only found that 10 chemical compounds regulate cumulative half suppression ratio IC to polymerization glutamic acid
50Less than the chemical inhibitor of 15 μ M, wherein tripterine can also reverse total length variation Huntingdon neuronal cell phenotype, is expected to be used for the treatment of Huntington's disease.List of references [5] tripterine protection is by MPTP and the inductive neurotoxicity of 3-nitropropionic acid, and its research conclusion is that tripterine is expected to become a neuroprotective and is used for treating parkinson (PD) and Heng Tingdunshi disease (HD).List of references [6] tripterine can hinder the death of neuronal cell and prolong the life-span of lateral spinal sclerosis disease (ALS) dna rat, might be the medicine of treatment people ALS disease.List of references [7] trehalose can alleviate the polymerization glutamic acid of court of a feudal ruler Dun Shi disease (HD) mouse model and regulate pathology.List of references [8] trehalose can suppress the accumulation and the neurotoxicity of β amyloplaste 40 and 42.Trehalose has effect at the origin cause of formation of Alzheimer (AD), but the treatment of Alzheimer (AD) is remained to be observed.
List of references
[1] number of patent application CN00107779.1
[2] the USA patent 5,880116 (1999)
[3] the USA number of patent application 20040220267
【4】BMC?Neuroscience?2005，6(1)，1-12
【5】Journal?of?Neurochemistry?2005，94，995
【6】Neurodegenerative?Diseases?2005；2：246-254
【7】Nat?Med.2004，10(2)：123-124
【8】Neurobiol?Dis?20(1)：74-81
Summary of the invention
The objective of the invention is, provide tripterine and trehalose to make capsular method, and proposed capsular function and usage.
In order to achieve the above object, the present invention adopts following technical scheme:
1, get the tripterine of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
2, get the trehalose of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
3, weigh the tripterine of 1 unit of weight, weigh the trehalose of 100-1000 unit of weight again;
4, with the tripterine of 1 unit of weight and the trehalose mix homogeneously of 1 unit of weight, obtain tripterine: the mixture of trehalose=1: 1;
5, the trehalose that adds 2 Unit Weights again obtains tripterine in said mixture: the mixture of trehalose=1: 3;
6, as step 5, increase progressively until obtaining tripterine with equivalent: the homogeneous mixture of trehalose=1: 100-1000;
7, with the homogeneous mixture capsulae vacuus of packing into, every capsules heavily is the 200-800 milligram, the capsule bottling, and every bottle of 30-200 grain, the bottleneck of obturaging, labelled, pretend;
8, usage: therapeutic dose dosage every day is by body weight 0.05-0.3 mg/kg; Preventive dose dosage every day is by body weight 0.01-0.1 mg/kg;
9, indication: be used for the prevention and the treatment of disease of nerve damage Alzheimer (AD), parkinson (PD), Heng Tingdunshi disease (HD), oblongata Duchenne-Arandisease (KD), lateral spinal sclerosis disease (ALS) and spinal cord injury.
The tripterine capsule of the present invention preparation, safe in utilization, easy, reasonable, economical, be applicable to large-scale production.
The specific embodiment
Embodiment 1:
1, get the tripterine of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
2, get the trehalose of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
3, weigh 1 kilogram of tripterine, weigh the trehalose of double centner again;
4, with 1 kilogram of tripterine and 1 kilogram of trehalose mix homogeneously, obtain tripterine: the mixture of trehalose=1: 1;
5, add 2 kilograms of trehaloses again in said mixture, obtain tripterine: the mixture of trehalose=1: 3;
6, as step 5, increase progressively until obtaining tripterine with equivalent: trehalose=1: the homogeneous mixture of double centner;
7, with the homogeneous mixture capsulae vacuus of packing into, every capsules heavily is 200 milligrams, the capsule bottling, and 30 every bottle, the bottleneck of obturaging, labelled, pretend;
8, usage: therapeutic dose dosage every day is by body weight 0.05 mg/kg; Preventive dose dosage every day is by body weight 0.01 mg/kg;
9, indication: be used for the prevention and the treatment of disease of nerve damage Alzheimer (AD), parkinson (PD), Heng Tingdunshi disease (HD), oblongata Duchenne-Arandisease (KD), lateral spinal sclerosis disease (ALS) and spinal cord injury.
Embodiment 2:
1, get the tripterine of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
2, get the trehalose of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
3, weigh 1 kilogram of tripterine, weigh 500 kilograms of trehaloses again;
4, with 1 kilogram of tripterine and 1 kilogram of trehalose mix homogeneously, obtain tripterine: the mixture of trehalose=1: 1;
5, add 2 kilograms of trehaloses again in said mixture, obtain tripterine: the mixture of trehalose=1: 3;
6, as step 5, increase progressively until obtaining tripterine: the homogeneous mixture of trehalose=1: 500 with equivalent;
7, with the homogeneous mixture capsulae vacuus of packing into, every capsules heavily is 500 milligrams, the capsule bottling, and 120 every bottle, the bottleneck of obturaging, labelled, pretend;
8, usage: therapeutic dose dosage every day is by body weight 0.15 mg/kg; Preventive dose dosage every day is by body weight 0.05 mg/kg;
9, indication: be used for the prevention and the treatment of disease of nerve damage Alzheimer (AD), parkinson (PD), Heng Tingdunshi disease (HD), oblongata Duchenne-Arandisease (KD), lateral spinal sclerosis disease (ALS) and spinal cord injury.
Embodiment 3:
1, get the tripterine of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
2, get the trehalose of the purity of an amount of weight greater than 98% natural origin, pulverize, cross 100 mesh sieves, 80 ℃ of oven dry;
3, weigh 1 kilogram of tripterine, weigh 1000 kilograms of trehaloses again;
4, with the tripterine of 1 unit of weight and the trehalose mix homogeneously of 1 unit of weight, obtain tripterine: the mixture of trehalose=1: 1;
5, add kilogram trehalose again in said mixture, obtain tripterine: the mixture of trehalose=1: 3;
6, as step 5, increase progressively until obtaining tripterine: the homogeneous mixture of trehalose=1: 1000 with equivalent;
7, with the homogeneous mixture capsulae vacuus of packing into, every capsules heavily is 800 milligrams, the capsule bottling, and 200 every bottle, the bottleneck of obturaging, labelled, pretend;
8, usage: therapeutic dose dosage every day is by body weight 0.3 mg/kg; Preventive dose dosage every day is by body weight 0.1 mg/kg;
9, indication: be used for the prevention and the treatment of disease of nerve damage Alzheimer (AD), parkinson (PD), Heng Tingdunshi disease (HD), oblongata Duchenne-Arandisease (KD), lateral spinal sclerosis disease (ALS) and spinal cord injury.
Claims (5)
1. in capsular prescription, tripterine: trehalose (weight ratio) is 1: 100-1000;
2. with equivalent incremental method mixing tripterine and trehalose, make two kinds of composition mix homogeneously;
3. capsular usage: therapeutic dose dosage every day is by body weight 0.05-0.3 mg/kg; Preventive dose dosage every day is by body weight 0.01-0.1 mg/kg;
4. capsular indication: be used for the prevention and the treatment of disease of nerve damage Alzheimer (AD), parkinson (PD), Heng Tingdunshi disease (HD), oblongata Duchenne-Arandisease (KD), lateral spinal sclerosis disease (ALS) and spinal cord injury.
5. effective ingredient is tripterine and trehalose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610200582 CN101091713A (en) | 2006-06-19 | 2006-06-19 | Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610200582 CN101091713A (en) | 2006-06-19 | 2006-06-19 | Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101091713A true CN101091713A (en) | 2007-12-26 |
Family
ID=38990271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610200582 Pending CN101091713A (en) | 2006-06-19 | 2006-06-19 | Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101091713A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200975A (en) * | 2019-07-18 | 2019-09-06 | 北京大学 | A kind of pharmaceutical composition and its application in preparation treatment neurodegenerative disease drug |
| CN111632057A (en) * | 2020-06-10 | 2020-09-08 | 青岛市中心医院 | Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance |
-
2006
- 2006-06-19 CN CN 200610200582 patent/CN101091713A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110200975A (en) * | 2019-07-18 | 2019-09-06 | 北京大学 | A kind of pharmaceutical composition and its application in preparation treatment neurodegenerative disease drug |
| CN110200975B (en) * | 2019-07-18 | 2022-06-28 | 北京大学 | Pharmaceutical composition and application thereof in preparing medicines for treating neurodegenerative diseases |
| CN111632057A (en) * | 2020-06-10 | 2020-09-08 | 青岛市中心医院 | Application of rhamnose monosulfate trisaccharide and derivatives in skeletal muscle atrophy resistance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1977908A (en) | Chinese medicine composition for treating cardio-cerebrovascular disease | |
| CN101091713A (en) | Tripterine capsule in use for preventing and treating disease of nerve damage, preparation method and usage | |
| CN101474236A (en) | Ganoderma lucidum wall-broken spore powder capsule | |
| JPS6226229A (en) | Nervous cell differentiation promoter | |
| CN110522783A (en) | A kind of drug and preparation method thereof can be used for neurodegenerative disease | |
| CN101601820A (en) | The manufacture method of calamus epilepsy-removing oral wine | |
| CN103191253A (en) | Medicine for treating anemia and preparation method thereof | |
| CN101757458A (en) | Traditional Chinese preparation for treating facial nerve spasm | |
| CN1899387B (en) | Method for preventing and treating child convulsion and its preparing method | |
| CN105749026A (en) | Traditional Chinese medicine preparation for treating epilepsy and preparation method of traditional Chinese medicine preparation | |
| CN107375829A (en) | Treat the Chinese medicine composition of Post-apoplectic and its preparation method of preparation | |
| CN103416746B (en) | Lipid-lowing selenium-rich tea pigment and production method thereof | |
| CN101904931A (en) | Medicament for treating beriberi and preparation method thereof | |
| CN102961438B (en) | Traditional Chinese medicine composition for treating rheumatism and rheumatoid arthritis and preparation method thereof | |
| CN101590114B (en) | Medicament for treating multiple sclerosis and preparation method thereof | |
| CN103877230A (en) | A medicine extract product used for preventing and/or treating senile dementia, a preparing method thereof, preparations thereof and applications thereof | |
| Link et al. | An overview of studies comparing the efficacy, safety, and tolerability of paroxetine and clomipramine | |
| CN102441084A (en) | External traditional Chinese medicine composition used for treating prolapse of lumbar intervertebral disc | |
| CN101757167A (en) | Plaster for treating diarrhea | |
| CN102283920B (en) | Medicinal composition for treating parkinson disease as well as preparation method and application thereof | |
| CN1055398C (en) | Medicament for treatment of hyerosteogeny and its prepn. | |
| Rahman et al. | Natural products in neuroprotective therapies: Experimental and cheminformatics approaches to manage neurological disorders | |
| Rahman et al. | Exploring the Natural Products for Experimental and Cheminformatics-based Therapeutics for Neurological Disorders: An update | |
| CN102441083A (en) | Externally-applied traditional Chinese medicine composition for treating acute soft tissue injury | |
| CN106668563A (en) | Traditional Chinese medicine for postoperative recovery nursing of bone injuries and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |